Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials [Statistical Analysis]

Conclusions When considering the entire course of treatment, the approved bortezomib dose exceeds the conventional ceiling DLT rate of 20% to 33%. Retrospective analysis of trial data provides an opportunity for dose optimization of MTAs. Future dose-finding studies of MTAs should take into account late-onset toxicities to ensure that a tolerable dose is identified for future efficacy and comparative trials.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Clinical Trials, Phase I and Clinical Pharmacology, Statistics in Oncology Statistical Analysis Source Type: research